To include your compound in the COVID-19 Resource Center, submit it here.

Captisol-enabled melphalan: Phase IIa data

An open-label, crossover Phase IIa trial in 15 patients showed that 100 mg/m 2

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE